为什么从“名词解释”开始？
（What's in a Name）
作者在第一章开头写了一段话，我读到时深以为然：
“Understanding the language used in any discipline or industry is paramount to being able to effectively communicate with others in the field. … So too, in the field of Chemistry Manufacturing & Control (CMC) regulatory compliance, language is most important.”
他说，计算机行业的人讲“terabytes and gigabytes”、金融圈的人说“ETFs and collateralized debt obligations”，CMC也有一套自己的语言。但和别的领域不一样——这套语言的每个词背后，都挂着一个监管含义。用错了，不是沟通不畅的问题，是申报可能面临被退的问题。
作者在这一章的首要任务，是把“Biologic/Biological, Biopharmaceutical/rDNA-derived以及ATMP/CGTP ”这三组核心的术语逐个拆解，讲清它们的演变和在监管眼中的含义。一、生物制品：不只是“来自生物”
（Biologic/Biological）
作者分别引用了FDA和EMA的官方定义。
FDA 对 biological products 的描述是：
“Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources – human, animal, or microorganism – and may be produced by biotechnology methods and other cutting-edge technologies.”
EMA 对 biological medicine 的定义是：
“A medicine whose active substance is made by a living organism. Assuring the quality of biological medicinal products is challenging, as they often consist of a number of product variants and process related impurities whose safety and efficacy profiles are difficult to predict. However, unlike chemical entities, toxic impurities are generally not an issue, and the safety issues of biological/biotechnological products are more often related to the mechanism of action of the biological product or to immunogenicity.”
两段定义放在一起，作者提炼出监管机构对“生物制品”的 三重共识定义：
来源：produced by or extracted from a living source（必须来源于活体系统或其提取物）
工艺：involves a challenging manufacturing process（其涉及的制造过程具备挑战性）
产品：is a complex product（为复杂产品）
为了解释何为缺一不可，作者给出了一个很有说服力的反例：抗生素（Antibiotic Drugs）
青霉素（Penicillin）、头孢菌素（Cephalosporins）这些药物，是通过微生物发酵生产的——满足条件1（来自活体）。但全球监管机构统一将它们归为化学药。
作者解释到，监管机构认为抗生素的发酵工艺相对成熟、不构成“challenging manufacturing process”；产品本身是小分子，结构明确，也不符合“complex product”的定义。所以即使来自活体，也不算生物制品（Biologic/Biological）。
这个三重共识框架，是贯穿全书的基础认知。后面所讲的内容都是建立在这个基础之上。
作者对于生物制品并没有停留在概念讲解，而是花了不少篇幅回顾生物制品的演进，进而传达出一个主旨，即生物制品的快速发展也伴随着定义的更新或产品的重新划分。
他梳理了四个典型的生物制品例子：
Animal-derived immune serums (anti-toxins)
这是最早的生物制品形态。19世纪末，von Behring 和 Kitasato 发现动物感染白喉/破伤风后产生的抗毒素可以用于治疗。作者引用了一段FDA的历史回顾：
“The late 19th century was one of the most exciting times imaginable for physicians and scientists working in biological research arenas around the world. … Their serum therapy was tested at Berlin's Charité hospital at the end of 1891 and the chemical company Hoechst began commercial antitoxin serum production soon after. Mortality rates from diphtheria in Europe dropped dramatically
and laboratories in the United States quickly rushed to begin production of these new life-saving biological products.”
这种被动免疫的方式后来大部分被疫苗取代，但蛇毒、蝎毒等抗毒血清至今仍在使用。
疫苗的起源通常追溯到18世纪末 Edward Jenner 用牛痘预防天花。但真正形成产业是在20世纪。他引用CDC的麻疹疫苗史：
“In the decade before 1963 when a vaccine became available, nearly all children got measles by the time they were 15 years of age. It is estimated 3 to 4 million people in the United States were infected each year. Also, each year, among reported cases, an estimated 400 to 500 people died, 48,000 were hospitalized, and 1,000 suffered encephalitis.”
作者特别指出：“a number of viral vaccines, in recent years, are now being produced using genetic engineering methods”——这条线索直接连到了后面要讲的“biopharmaceutical”概念。疫苗本身是biologic，但用基因工程方法生产的疫苗，同时也是biopharmaceutical，这也是生物制品演变的缩影。
Human plasma-derived proteins
Edwin Cohn 在二战期间开发的低温乙醇分馏法，使得从血浆中分离白蛋白、免疫球蛋白、凝血因子成为可能。作者列出了一些目前市场上的血浆蛋白产品，并同样指出：其中一些现在也已经用基因工程方法生产了。
Therapeutic hormonal proteins
该产品为“技术进化论”的典型代表了。这里最出名的产品是胰岛素，一开始是在1922年 Banting 和 Best 从狗胰腺提取胰岛素救了一个14岁男孩。但当时几乎所有的胰岛素都来源于猪和牛的胰腺，其生产效率十分低下，原文写到
“it is estimated that it took two tons of pig pancreases to yield only 8 ounces (~200 grams) of porcine insulin.”
据估计，仅生产8盎司（约200克）的猪胰岛素就需要两吨猪胰腺。如今胰岛素已可通过基因工程技术实现高效生产
生长激素（human growth hormone）的故事更触目惊心。早期只能从尸体垂体提取，后来发现会传播 Creutzfeldt-Jakob 病（一种由朊病毒引起的致命神经疾病），被监管要求撤市。而正是这些天然来源的生物制品，带动了病毒灭活验证、TSE风险控制等一系列CMC安全策略的建立。今天我们在监管指南里读到的那些要求，背后都有血淋淋的真实安全事件作为驱动。
二、生物制药：一个被滥用的词
（Biopharmaceutical）
讲完biologic，作者开始讲解本书的核心——biopharmaceutical。
他先引用了 Merriam-Webster 词典的定义：
“a pharmaceutical derived from biological sources and especially one produced by biotechnology”
“the manipulation (as through genetic engineering) of living organisms or their components to produce useful commercial products”
基于这些定义，可以看出biopharmaceutical 其实是 biologic 的子集（subset）。作者总结的biopharmaceutical三重要素是：
必须由或从 基因工程改造的 活体来源生产或提取
涉及具有挑战性的制造工艺
是复杂的产品
和前面biologic的定义对比，唯一的新增条件就是 “genetically engineered（基因工程改造的）”。
但“biopharmaceuticals”这个词却面临了一个现实问题，即这个词已经被滥用了。
“Unfortunately, the term ‘biopharmaceutical’ has since been hijacked by the popular press, and is now being loosely defined as ‘biohealth’.”
除了将biopharmaceuticals=biohealth（生物健康），另一个例子则是维基百科把这个词扩大到包括 vaccines, whole blood, blood components, allergenics 等。药企的网站上也常把化学合成的抗病毒药叫 biopharmaceutical。
监管机构注意到了这种泛化，因此现在几乎不使用 biopharmaceutical 这个词：
“Regulatory authorities are aware of this hijacking … Therefore, they have rarely used this term.”
现如今监管机构更倾向使用 “recombinant DNA-derived”、“rDNA-derived”、“genetically modified” 这些表述。
而作者特别强调，在这本书里他所使用的“biopharmaceutical”依然是其原始定义。同时，“biopharmaceutical”，“recombinant DNA-derived”，“rDNA-derived”三个词会在书中交替使用，但其含义相同。
进入21世纪后，两个新术语开始出现在监管机构的指导文件和沟通材料中：ATMP（Advanced Therapy Medicinal Product，先进治疗药品）和 CGTP（Cell & Gene Therapy Product，细胞和基因治疗产品）。
EMA 对 ATMP 的三分类：
先进治疗药物（ATMPs）是基于基因、组织或细胞的医用药物，为疾病和损伤的治疗带来革命性突破。此类药物主要分为三大类：基因治疗药物；体细胞治疗药物；组织工程药物
EMA官方原文如下：
“Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. ATMPs can be classified into three main types:
gene therapy medicines: these contain genes that lead to a therapeutic, prophylactic or diagnostic effect. They work by inserting ‘recombinant’ genes into the body, usually to treat a variety of diseases, including genetic disorders, cancer or long-term diseases. A recombinant gene is a stretch of DNA that is created in the laboratory, bringing together DNA from different sources;
somatic-cell therapy medicines: these contain cells or tissues that have been manipulated to change their biological characteristics or cells or tissues not intended to be used for the same essential functions in the body. They can be used to cure, diagnose or prevent diseases;
tissue-engineered medicines: these contain cells or tissues that have been modified so they can be used to repair, regenerate or replace human tissue”
FDA 对 CGTP 的定义：
细胞治疗产品包括细胞免疫疗法、癌症疫苗，以及适用于特定治疗用途的其他自体或同种异体细胞类型，例如造血干细胞、成体干细胞和胚胎干细胞。人类基因治疗是指通过导入遗传物质来修饰或调控基因产物的表达，或改变活细胞的生物学特性以达到治疗目的的技术。
FDA官方原文如下：
“Cellular therapy products include cellular immunotherapies, cancer vaccines, and other types of both autologous and allogeneic cells for certain therapeutic indications, including hematopoetic stem cells and adult and embryonic stem cells. Human gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use.”
作者指出本质上ATMP 和 CGTP 覆盖的是同一类产品，只是 EMA 偏好 ATMP，FDA 偏好 CGTP。他预测未来可能统一为 “advanced therapies”。
此外，作者提到 FDA还引入了另一个术语 - RMAT（Regenerative Medicine Advanced Therapy，再生医学疗法），强调这不是一个新的产品分类，而是一种加速审评的资格认定，需要满足三个条件：
即该药品属于再生医学疗法（如细胞疗法，人体细胞等）；该药品旨在治疗、改善、逆转或治愈严重或危及生命的疾病或病症；初步临床证据表明该药品具备满足此类疾病或病症未尽医疗需求的潜力。
“(a) The drug is a regenerative medicine therapy … (b) The drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (c) Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs.”
产品被归为哪个类别，直接决定了它的申报路径，如第二章详细展开的（BLA vs NDA）、审评中心（CBER vs CDER）、以及适用的法规框架（PHS Act §351 vs FD&C Act §505）
biopharmaceutical 的泛化是一个典型例子。写技术文件时，建议对照FDA/EMA的官方术语体系，而不是按行业约定俗成的习惯来
biopharmaceutical：基因工程改造是必须
作者在书里反复强调：化学合成的寡核苷酸、多肽不是；传统疫苗不是；血浆蛋白（如果不是重组表达的）也不是。这个边界在后续章节讨论时特别重要
本章的核心“Biopharmaceutical Landscape”，由产品演进的“四波浪潮”组成，即“重组蛋白→单抗→生物类似药→基因治疗”（如下图所示）。内容会在后续逐渐推送，敬请期待。
图片来源：Geigert, The Challenge of CMC Regulatory Compliance for Biopharmaceuticals, 4th ed., Chap. 1.
本号所有内容仅为个人学习心得与行业技术交流，不构成任何研发申报、投资决策的专业建议，具体操作请严格遵循现行法规与行业规范。
本号会尽力确保内容的准确和完整，但仍然可能存在理解不当之处，您可在公众号对话框或评论区中发送反馈，笔者会尽快予以回复讨论并纠正。
本文所引用英文原文摘自《The Challenge of CMC Regulatory Compliance for Biopharmaceuticals》第四版，版权归原作者及出版社所有，此处仅供非商业学习交流。
